A pivotal study of bb-2121 in patients with relapsed/refractory third line multiple myeloma
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2018
At a glance
- Drugs Bb 2121 (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 02 Aug 2018 According to a bluebird bio media release, trial is planned to initiate in 2H 2018.
- 04 May 2017 New trial record
- 27 Apr 2017 According to a Celgene Corporation media release, Celgene and bluebird bio plan to initiate this trial by year-end.